Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study.

Détails

ID Serval
serval:BIB_3742A8D722D8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Long-term Efficacy of TNF-alpha Inhibitors on Persistent Uveitic Macular Edema: A Swiss Multicenter Cohort Study.
Périodique
Ocular immunology and inflammation
Auteur⸱e⸱s
Bograd A., Fuchs D., Bächtiger J., Pfister I.B., Spindler J., Hoogewoud F., Gugleta K., Böni C., Guex-Crosier Y., Garweg J.G., Tappeiner C.
ISSN
1744-5078 (Electronic)
ISSN-L
0927-3948
Statut éditorial
In Press
Peer-reviewed
Oui
Pages
1-8
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Résumé
To assess the efficacy of tumor necrosis factor-alpha inhibitors (TNFi) on uveitic macular edema (ME) unresponsive to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).
This multicenter retrospective study included patients with uveitic ME persisting despite csDMARDs. The effect of an additional TNFi on central retinal thickness (CRT), best corrected visual acuity (BCVA) and corticosteroid need was evaluated.
Thirty-five eyes (26 patients, mean age 42.9 ± 15.2 years) were included. CRT decreased from 425 ± 137 µm to 294 ± 66 µm (p < .001) and 280 ± 48 µm (p < .001) at 1 and 4 years of follow-up, respectively. BCVA improved from 0.28 ± 0.22 to 0.21 ± 0.48 (1 year, p = .013) and 0.08 ± 0.13 logMAR (4 years, p = .002). The proportion of patients requiring systemic corticosteroids decreased from 88.5% to 34.8% (1 year) and 15.4% (4 years).
The addition of a TNFi resulted in an improvement of CRT and BCVA for up to 4 years in uveitic ME but rescue treatments were needed for some patients.
Mots-clé
Adalimumab, TNF-alpha inhibitors, infliximab, macular edema, uveitis
Pubmed
Web of science
Création de la notice
24/05/2022 8:58
Dernière modification de la notice
02/07/2022 6:34
Données d'usage